

REMARKS

In the Office Action mailed in the above-referenced application on November 16, 2005, a restriction requirement was made by the Examiner to pending claims 1-36. The claims were placed into the following twenty four groups:

Group 1: Claims 1-6, 9, 10 and 12 (in part), drawn to compounds of formula I wherein X is N; R¹ is an aryl group; and A is Q;

Group 2: Claims 1-6, 9, 10 and 12 (in part), drawn to compounds of formula I wherein X is N; R¹ is a heteroaryl group; and A is Q;

Group 3: Claims 1-12 (in part), drawn to compounds of formula I wherein X is N; R¹ is an aryl group; A is -(U)_nZ; and Z is a ring system having a (5-membered ring)=N;

Group 4: Claims 1-12 (in part), drawn to compounds of formula I wherein X is N; R¹ is a heteroaryl group; A is -(U)_nZ; and Z is a ring system having a (5-membered ring)=N;

Group 5: Claims 1-6 and 9-12 (in part), drawn to compounds of formula I wherein X is N; R¹ is an aryl group; A is -(U)_nZ; and Z is a ring system having a (6-membered ring)=N;

Group 6: Claims 1-6 and 9-12 (in part), drawn to compounds of formula I wherein X is N; R¹ is a heteroaryl group; A is -(U)_nZ; and Z is a ring system having a (6-membered ring)=N;

Group 7: Claims 1-6, 9, 10 and 12 (in part), drawn to compounds of formula I wherein X is CH, CF or C-CN; R¹ is an aryl group; and A is Q;

Group 8: Claims 1-6, 9, 10 and 12 (in part), drawn to compounds of formula I wherein X is CH, CF or C-CN; R¹ is a heteroaryl group; and A is Q;

Group 9: Claims 1-12 (in part), drawn to compounds of formula I wherein X is CH, CF or C-CN; R¹ is an aryl group; A is -(U)_nZ; and Z is a ring system having a (5-membered ring)=N;

Group 10: Claims 1-12 (in part), drawn to compounds of formula I wherein X is CH, CF or C-CN; R¹ is a heteroaryl group; A is -(U)_nZ; and Z is a ring system having a (5-membered ring)=N;

Group 11: Claims 1-6 and 9-12 (in part), drawn to compounds of formula I wherein X is CH, CF or C-CN; R¹ is an aryl group; A is -(U)_nZ; and Z is a ring system having a (6-membered ring)=N;

Group 12: Claims 1-6 and 9-12 (in part), drawn to compounds of formula I wherein X is CH, CF or C-CN; R¹ is a heteroaryl group; A is -(U)_nZ; and Z is a ring system having a (6-membered ring)=N;

Group 13: Claims 13-18, 21, 22 and 24 (in part), drawn to a method of treating hyperproliferative diseases using compounds of formula I wherein X is N, R¹ is an aryl group; and A is Q;

Group 14: Claims 13-18, 21, 22 and 24 (in part), drawn to a method of treating hyperproliferative diseases using compounds of formula I wherein X is N, R¹ is a heteroaryl group; and A is Q;

Group 15: Claims 13-24 (in part), drawn to a method of treating hyperproliferative diseases using compounds of formula I wherein X is N; R¹ is an aryl group; A is -(U)_nZ; and Z is a ring system having a (5-membered ring)=N;

Group 16: Claims 13-24 (in part), drawn to a method of treating hyperproliferative diseases using compounds of formula I wherein X is N; R¹ is a heteroaryl group; A is -(U)_nZ; and Z is a ring system having a (5-membered ring)=N;

Group 17: Claims 13-18 and 21-24 (in part), drawn to a method of treating hyperproliferative diseases using compounds of formula I wherein X is N; R¹ is an aryl group; A is -(U)_nZ; and Z is a ring system having a (6-membered ring)=N;

Group 18: Claims 13-18 and 21-24 (in part), drawn to a method of treating hyperproliferative diseases using compounds of formula I wherein X is N; R¹ is a heteroaryl group; A is -(U)_nZ; and Z is a ring system having a (6-membered ring)=N;

Group 19: Claims 13-18, 21, 22 and 24 (in part), drawn to a method of treating hyperproliferative diseases using compounds of formula I wherein X is CH, CF or C-CN; R¹ is an aryl group; and A is Q;

Group 20: Claims 13-18, 21, 22 and 24 (in part), drawn to a method of treating hyperproliferative diseases using compounds of formula I wherein X is CH, CF or C-CN; R¹ is a heteroaryl group; and A is Q;

Group 21: Claims 13-24 (in part), drawn to a method of treating hyperproliferative diseases using compounds of formula I wherein X is CH, CF or C-CN; R¹ is an aryl group; A is -(U)_nZ; and Z is a ring system having a (5-membered ring)=N;

Group 22: Claims 13-24 (in part), drawn to a method of treating hyperproliferative diseases using compounds of formula I wherein X is CH, CF or C-CN; R¹ is a heteroaryl group; A is -(U)_nZ; and Z is a ring system having a (5-membered ring)=N;

Group 23: Claims 13-18 and 21-24 (in part), drawn to a method of treating


hyperproliferative diseases using compounds of formula I wherein X is CH, CF or C-CN; R¹ is an aryl group; A is -(U)_nZ; and Z is a ring system having a (6-membered ring)=N; and

Group 24: Claims 13-18 and 21-24 (in part), drawn to a method of treating hyperproliferative diseases using compounds of formula I wherein X is CH, CF or C-CN; R¹ is a heteroaryl group; A is -(U)_nZ; and Z is a ring system having a (6-membered ring)=N.

This restriction requirement is respectfully traversed. It is believed that the Examiner has not demonstrated a proper basis for the proposed restriction of R¹, and it would not be an undue burden for the examiner to search both aryl and heteroaryl groups during his search of class 544.

However, in order to advance prosecution, an election is hereby made with traverse to prosecute the invention of Group 3 (claims 1-12, in part), drawn to compounds of formula I wherein X is N; R¹ is an aryl group; A is -(U)_nZ; and Z is a ring system having a (5-membered ring)=N. In addition, claims 1, 7 and 8 have been amended to cancel nonelected subject matter.

The Examiner further states that an election of a species is also required for the elected group. Accordingly, an election is made for the following single compound, which finds support in Example 45 of the application as filed:



In addition, new claims 25-36 have been added to more completely claim the invention. New claims 25-36 belong to the elected Group 3, and it is respectfully requested that claims 25-36 be examined along with the claims of Group 3. Specifically, new claim 25 further defines the R¹ groups. New claims 26-31 further define the Z group, wherein W is oxygen. New claims 32-35 further define the Z group, wherein W is CH₂. New claim 36 recites specific compounds of Group 3 as provided in Examples 31-48. Support for new claims 25-36 can be found throughout the Specification in general and in Examples 31-48. No new matter has been added by this amendment. Reconsideration of the claims is respectfully requested.

PETITION FOR 1-MONTH EXTENSION AND FEES DUE

The undersigned hereby petitions for a 1-month extension to which to extend the due date for response to January 17, 2006 (January 16, 2006 being a federal holiday). The enclosed check for \$720 includes the large entity petition fee for the 1-month extension and the excess claims fee required for the additional dependent claims. The Examiner is authorized to charge any fee deficiency associated with this response to Deposit Account No. 50-1123.

Respectfully submitted,



January 17, 2006

Carol W. Burton, Reg. No. 35,465
Hogan & Hartson L.L.P.
1200 17th Street, Suite 1500
Denver, CO 80202
Telephone: (303) 454-2454
Facsimile: (303) 899-7333